تحليلات المنتج الاختيارية
بإذنك، نستخدم تحليلات محدودة تراعي الخصوصية لفهم مسارات البحث الفعالة. لا نستخدم أدوات تتبع إعلانية أو تسجيل الجلسات. يمكنك تغيير هذا الخيار في التفضيلات. اقرأ سياسة الخصوصية.
Elevance Health Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $94.1B | |
|---|---|---|
| Revenue (ttm) | 201.8B | |
| Net income (ttm) | 5.1B | |
| EPS (ttm) | $23.4 | |
| Shares out | 216.1M | |
| P/E (trailing) | 17.6x | |
| P/E (forward) | 13.7x | |
| Dividend | $6.88 (1.67%) | |
| Volume | 858,930 | |
| Beta | 0.71 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $138.64B | $156.60B | $171.34B | $177.01B | $199.13B | +9.5% |
| Gross profit | $35.99B | $39.95B | $47.01B | $49.24B | $50.90B | +9.1% |
| Operating income | $7.56B | $8.28B | $8.50B | $7.86B | $7.20B | -1.2% |
| Net income | $6.16B | $5.89B | $5.99B | $5.98B | $5.66B | -2.1% |
| EPS (diluted) | $24.95 | $24.28 | $25.22 | $25.68 | $25.21 | +0.3% |
| EBITDA | $10.03B | $10.13B | $10.49B | $10.48B | $9.66B | -0.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $15.92B | $17.70B | $20.09B | $20.03B | $20.98B | +7.2% |
Recent company headlines from major financial publishers.
Medicare Advantage underwriting margins accelerate toward management target ranges ahead of schedule, supported by Star Rating recoveries and favorable claims development. Carelon secures major third-party external selling wins, expanding service operating margins substantially. Consolidated operating margins expand meaningfully, driving accelerated annual adjusted earnings growth with valuation multiple expansion.
Elevance executes disciplined commercial pricing resets matching low-double-digit cost inflation while state Medicaid rate adjustments gradually restore underwriting margins. Carelon continues steady 5% revenue expansion with 5.3% pharmacy operating margins. Consolidated operating margins normalize from 3.6% in 2025 to 4.2% by 2030, supporting our fair value midpoint of $474.64 (+9.33% implied upside).
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.4% | $513 | $525 | $538 | $553 | $570 |
| 7.9% | $483 | $493 | $504 | $516 | $529 |
| 8.4% | $458 | $466 | $475 | $484 | $495 |
| 8.9% | $436 | $442 | $450 | $458 | $466 |
| 9.4% | $416 | $422 | $428 | $435 | $442 |
Upcoming earnings date and setup when available.
التصنيف الذي حملته نسخة البحث المنشورة في كل شهر. يقارن التصنيف السعر في تاريخ التحليل بالقيمة العادلة، وليس سجلاً لمدى صحة التقدير.
| السنة | يناير | فبراير | مارس | أبريل | مايو | يونيو | يوليو | أغسطس | سبتمبر | أكتوبر | نوفمبر | ديسمبر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
